Helicobacter Pylori Infections Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, Involved by DelveInsight | Phathom Pharma, HK inno.N Corporation, Elpen Pharma, Deva Holding

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Helicobacter Pylori Infections pipeline constitutes 5+ key companies continuously working towards developing 5+ Helicobacter Pylori Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Helicobacter Pylori Infections Pipeline Insight, 2024 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Helicobacter Pylori Infections Market.

 

The Helicobacter Pylori Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Helicobacter Pylori Infections Pipeline Report: 

Companies across the globe are diligently working toward developing novel Helicobacter Pylori Infections treatment therapies with a considerable amount of success over the years. 

Helicobacter Pylori Infections companies working in the treatment market are Servatus Biopharmaceuticals, TenNor Therapeutics (Suzhou) Limited, Phathom Pharmaceuticals, Inc., HK inno.N Corporation, Elpen Pharmaceutical Co. Inc., Deva Holding A.S., Lallemand Health Solutions, Takeda, Meridian Bioscience, Inc., Janssen Cilag Pharmaceutica S.A.C.I., Greece, RedHill Biopharma Limited, Il-Yang Pharm. Co., Ltd., Asan Medical Center, MerLion Pharmaceuticals GmbH, TenNor Therapeutics (Suzhou) Limited, and others, are developing therapies for the Helicobacter Pylori Infections treatment 

Emerging Helicobacter Pylori Infections therapies in the different phases of clinical trials are- SVT1C4610, TNP-2198, Vonoprazan, Tegoprazan, Esomeprazole, Levofloxacin, Lacidofil, CJ-12420/Clarithromycin/AmoxicillinVonoprazan, Vonoprazan, Lansoprazole (Lanton), rabeprazole sodium, RHB-105, Ilaprazole + Amoxicillin, pantoprazole, Finafloxacin + Amoxicillin, Rifasutenizol capsules, and others are expected to have a significant impact on the Helicobacter Pylori Infections market in the coming years.   

In May 2022, Biomerica, Inc. announced CE Mark for its hp+detect diagnostic test that detects Helicobacter pylori bacteria. The company will begin to market and sell its hp+detect diagnostic test in the European Union (EU) and other international countries following the registration of the product in each country in which it is sold. Source: https://www.mordorintelligence.com/industry-reports/helicobacter-pylori-diagnostics-market

Bio-Rad launched Platelia H. Pylori IgG, an immuno-enzymatic assay for qualitative determination of IgG antibodies, in July 2022. Serology is a non-invasive, delicate, and straightforward technique for identifying H. pylori infection. The Platelia H. Pylori IgG immunoenzymatic assay is used to determine the quality of IgG antibodies.

 

Helicobacter Pylori Infections Overview

Helicobacter pylori (H. pylori) is a type of bacteria that infects the stomach lining and can cause various gastrointestinal issues. It is a common infection, affecting about half of the world’s population. H. pylori infections are usually acquired during childhood and can persist for many years if left untreated. 

 

Get a Free Sample PDF Report to know more about Helicobacter Pylori Infections Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/helicobacter-pylori-infections-pipeline-insight

 

Emerging Helicobacter Pylori Infections Drugs Under Different Phases of Clinical Development Include:

SVT1C4610: Servatus Biopharmaceuticals

TNP-2198: TenNor Therapeutics (Suzhou) Limited

Vonoprazan: Phathom Pharmaceuticals, Inc.

Tegoprazan: HK inno.N Corporation

Esomeprazole: Elpen Pharmaceutical Co. Inc.

Levofloxacin: Deva Holding A.S.

Lacidofil: Lallemand Health Solutions

CJ-12420/Clarithromycin/AmoxicillinVonoprazan: HK inno.N Corporation

Vonoprazan: Takeda

Lansoprazole (Lanton): Meridian Bioscience, Inc.

rabeprazole sodium: Janssen Cilag Pharmaceutica S.A.C.I., Greece

RHB-105: RedHill Biopharma Limited

Ilaprazole + Amoxicillin: Il-Yang Pharm. Co., Ltd.

pantoprazole: Asan Medical Center

Finafloxacin + Amoxicillin: MerLion Pharmaceuticals GmbH

Rifasutenizol capsules: TenNor Therapeutics (Suzhou) Limited

 

Helicobacter Pylori Infections Route of Administration

Helicobacter Pylori Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

Oral

Parenteral

Intravenous

Subcutaneous

Topical

 

Helicobacter Pylori Infections Molecule Type

Helicobacter Pylori Infections Products have been categorized under various Molecule types, such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy 

 

Helicobacter Pylori Infections Pipeline Therapeutics Assessment

Helicobacter Pylori Infections Assessment by Product Type

Helicobacter Pylori Infections By Stage and Product Type

Helicobacter Pylori Infections Assessment by Route of Administration

Helicobacter Pylori Infections By Stage and Route of Administration

Helicobacter Pylori Infections Assessment by Molecule Type

Helicobacter Pylori Infections by Stage and Molecule Type

 

DelveInsight’s Helicobacter Pylori Infections Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I)

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

 

Further Helicobacter Pylori Infections product details are provided in the report. Download the Helicobacter Pylori Infections pipeline report to learn more about the emerging Helicobacter Pylori Infections therapies

 

 

Some of the key companies in the Helicobacter Pylori Infections Therapeutics Market include:

Key companies developing therapies for Helicobacter Pylori Infections are – Takeda Pharmaceutical, AbbVie, Cumberland Pharmaceuticals, Eisai Co, Bio-Rad Laboratories, F. Hoffmann-La, Roche, Alpha Laboratories, Biohit, Biomerica, Inc., QuickNaviTM, and others.

 

Helicobacter Pylori Infections Pipeline Analysis:

The Helicobacter Pylori Infections pipeline report provides insights into 

The report provides detailed insights about companies that are developing therapies for the treatment of Helicobacter Pylori Infections with aggregate therapies developed by each company for the same.

It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Helicobacter Pylori Infections Treatment.

Helicobacter Pylori Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Helicobacter Pylori Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Helicobacter Pylori Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Helicobacter Pylori Infections drugs and therapies

 

Scope of Helicobacter Pylori Infections Pipeline Drug Insight    

Coverage: Global

Key Helicobacter Pylori Infections Companies: Servatus Biopharmaceuticals, TenNor Therapeutics (Suzhou) Limited, Phathom Pharmaceuticals, Inc., HK inno.N Corporation, Elpen Pharmaceutical Co. Inc., Deva Holding A.S., Lallemand Health Solutions, Takeda, Meridian Bioscience, Inc., Janssen Cilag Pharmaceutica S.A.C.I., Greece, RedHill Biopharma Limited, Il-Yang Pharm. Co., Ltd., Asan Medical Center, MerLion Pharmaceuticals GmbH, TenNor Therapeutics (Suzhou) Limited, and others

Key Helicobacter Pylori Infections Therapies: SVT1C4610, TNP-2198, Vonoprazan, Tegoprazan, Esomeprazole, Levofloxacin, Lacidofil, CJ-12420/Clarithromycin/AmoxicillinVonoprazan, Vonoprazan, Lansoprazole (Lanton), rabeprazole sodium, RHB-105, Ilaprazole + Amoxicillin, pantoprazole, Finafloxacin + Amoxicillin, Rifasutenizol capsules, and others

Helicobacter Pylori Infections Therapeutic Assessment: Helicobacter Pylori Infections current marketed and Helicobacter Pylori Infections emerging therapies

Helicobacter Pylori Infections Market Dynamics: Helicobacter Pylori Infections market drivers and Helicobacter Pylori Infections market barriers 

 

Request for Sample PDF Report for Helicobacter Pylori Infections Pipeline Assessment and clinical trials

 

Table of Contents

1. Helicobacter Pylori Infections Report Introduction

2. Helicobacter Pylori Infections Executive Summary

3. Helicobacter Pylori Infections Overview

4. Helicobacter Pylori Infections- Analytical Perspective In-depth Commercial Assessment

5. Helicobacter Pylori Infections Pipeline Therapeutics

6. Helicobacter Pylori Infections Late Stage Products (Phase II/III)

7. Helicobacter Pylori Infections Mid Stage Products (Phase II)

8. Helicobacter Pylori Infections Early Stage Products (Phase I)

9. Helicobacter Pylori Infections Preclinical Stage Products

10. Helicobacter Pylori Infections Therapeutics Assessment

11. Helicobacter Pylori Infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Helicobacter Pylori Infections Key Companies

14. Helicobacter Pylori Infections Key Products

15. Helicobacter Pylori Infections Unmet Needs

16 . Helicobacter Pylori Infections Market Drivers and Barriers

17. Helicobacter Pylori Infections Future Perspectives and Conclusion

18. Helicobacter Pylori Infections Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×